Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lumacaftor monotherapy

Next Previous
X
Search
Drug Profile

Lumacaftor monotherapy

Alternative Names: Corrector VX-809; VRT-826809; VX-809

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
  • Developer Vertex Pharmaceuticals
  • Class Amides; Antihaemorrhagics; Benzodioxoles; Benzoic acids; Cyclopropanes; Fluorinated hydrocarbons; Heart failure therapies; Pyridines; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cystic fibrosis

Most Recent Events

  • 02 Nov 2020 Royalty Pharma updates royalty agreement
  • 23 Feb 2017 Vertex Pharmaceuticals has patent protection for lumacaftor in USA and European Union (Vertex Pharmaceuticals form 10-K, filed in February 2017)
  • 06 Oct 2015 Discontinued - Phase-III for Cystic fibrosis in Canada, Belgium, Netherlands, Germany, USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top